Russia Says It Started Producing Virus Vaccine, Saudis to Conduct Clinical Trials

The vaccine has been named 'Sputnik V' in homage to the world's first satellite launched by the Soviet Union

Reuters
Haaretz
Send in e-mailSend in e-mail
FILE Photo: Russian President Vladimir Putin, left, shakes hands with Saudi Arabia Crown Prince Mohammed bin Salman during their meeting in Moscow, Russia, June 14, 2018.
FILE Photo: Russian President Vladimir Putin, left, shakes hands with Saudi Arabia Crown Prince Mohammed bin Salman during their meeting in Moscow, Russia, June 14, 2018.Credit: Alexei Druzhinin/AP
Reuters
Haaretz

Russia has produced the first batch of its new vaccine for COVID-19, the Interfax news agency quoted the health ministry as saying on Saturday, hours after the ministry reported the start of manufacturing. The head of Russia's sovereign wealth fund also said that Saudi Arabia would conduct clinical trials on the new vaccine.

Some scientists said they fear that with this fast regulatory approval Moscow may be putting national prestige before safety amid the global race to develop a vaccine against the disease.

Russia has said the vaccine, the first for the coronavirus to go into production, will be rolled out by the end of this month. 

Russians are working with a pharmaceutical company in Saudi Arabia to conduct clinical trials for the vaccine and have sharing data from Phase I and Phase II trials with partners in the kingdom, the chief executive officer of the Russian Direct Investment Fund, Kirill Dmitriev, told Arab News. Dmitriev's announcement also included a data sharing agreement with the UAE.

Its approval comes before trials that would normally involve thousands of participants, commonly known as Phase III. Such trials are usually considered essential precursors for a vaccine to secure regulatory approval.

The vaccine has been named "Sputnik V" in homage to the world's first satellite launched by the Soviet Union. President Vladimir Putin has assured the public that it is safe, adding that one of his daughters had taken it as a volunteer and felt good afterwards.

Moscow's Gamaleya Institute, which developed the vaccine, said previously that Russia would be producing about 5 million doses a month by December-January, Interfax said.